Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228039 · ClinicalTrials.gov registry record · Phase 4
ESP Blocks for Posterior Spinal Fusion
A Phase 4 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT07228039 is a Phase 4 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 75 participants.
The verdict
NCT07228039, a Phase 4 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.
Interventions
- DRUG ESP Block with Bupivacaine
- DRUG ESP Block with Bupivacaine + Liposomal Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07228039
The ClinicalTrials.gov registry entry for NCT07228039 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ESP Block with Bupivacaine is the first listed.
NCT07228039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07228039 about?
NCT07228039 is a clinical study titled "ESP Blocks for Posterior Spinal Fusion". This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outc...
What is the current status of trial NCT07228039?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2026-07. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07228039?
The interventions under investigation include: ESP Block with Bupivacaine (DRUG), ESP Block with Bupivacaine + Liposomal Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT07228039?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.